ARO-MAPT-SC Tau ASO Trial (NCT07221344)

Overview

Overview

ARO-MAPT-SC is a Phase 1/2a clinical trial evaluating a novel tau-targeting RNA interference (RNAi) therapeutic developed by Arrowhead Pharmaceuticals. The trial investigates ARO-MAPT-SC in healthy subjects and patients with early Alzheimer's disease["@arrowhead2025"].

This represents a groundbreaking approach to Alzheimer's disease therapy by targeting tau pathology at its source—the genetic level. Unlike antibody-based approaches that clear existing tau protein, RNAi therapeutics can reduce tau production before pathological accumulation occurs.

Trial Details

| Attribute | Details |
|-----------|---------|
| NCT Number | NCT07221344 |
| Phase | Phase 1/2a |
| Status | Recruiting |
| Sponsor | Arrowhead Pharmaceuticals |
| Enrollment | 112 participants |
| Start Date | November 18, 2025 |
| Expected Completion | June 2027 |
| Location | Grafton, Auckland, New Zealand |
| Administration | Subcutaneous injection |

Tau Pathology in Alzheimer's Disease

The Tau Protein

Tau (MAPT - Microtubule-Associated Protein Tau) is a protein that stabilizes microtubules in neurons. In Alzheimer's disease and related tauopathies, tau becomes hyperphosphorylated, leading to:

• Neurofibrillary Tangle Formation: Paired helical filaments of hyperphosphorylated tau
• Microtubule Dysfunction: Loss of tau's normal microtubule-stabilizing function
• Synaptic Loss: Tau pathology correlates with synaptic dysfunction
• Neuronal Death: Progressive neurodegeneration follows tau accumulation

Tau Spread Hypothesis

Recent research supports the concept that tau pathology spreads prion-like through connected brain regions:

The Amyloid-Tau Relationship

The relationship between amyloid and tau pathology is complex:

• Amyloid-Independent Tau: Tau pathology can occur without significant amyloid
• Amyloid Potentiation: Amyloid may accelerate tau pathology
• Sequential Model: Amyloid triggers tau which mediates neurodegeneration
• Threshold Effects: Both pathologies must exceed thresholds for clinical symptoms

Mechanism of Action

RNA Interference Technology

ARO-MAPT-SC employs RNA interference to reduce tau expression. The mechanism involves several steps[@becher2023]:

1. siRNA Delivery

• TRiM™ Platform: Arrowhead's Targeted RNAi Molecule platform
• Cellular Uptake: siRNA enters cells via endocytosis
• Endosomal Escape: Proprietary chemistry enables release from endosomes

2. RNA-Induced Silencing Complex (RISC) Loading

• Guide Strand Selection: One siRNA strand becomes the guide
• RISC Incorporation: The siRNA-RISC complex scans for complementary mRNA
• Catalytic Activity: One RISC complex can destroy multiple mRNA molecules

3. Target mRNA Degradation

• Sequence Complementarity: siRNA guide binds to MAPT mRNA
• Endonucleolytic Cleavage: Argonaute protein cuts the mRNA
• mRNA Degradation: Cleaved mRNA is degraded by cellular machinery
• Reduced Protein Translation: Fewer tau protein molecules produced

Advantages Over Antibody Approaches

RNAi offers several potential advantages:

| Feature | RNAi (ARO-MAPT-SC) | Antibody Approach |
|---------|-------------------|-------------------|
| Target | Genetic level (mRNA) | Protein level |
| Effect | Reduces production | Clears existing protein |
| Duration | Extended with subcutaneous dosing | Requires repeated infusions |
| Distribution | TRiM™ enables CNS delivery | Limited BBB penetration |
| Mechanism | Gene silencing | Protein clearance |

The TRiM™ Platform

Arrowhead's TRiM™ platform represents advances in siRNA delivery:

• Targeting Ligands: Multiple options for tissue-specific delivery
• Endosomal Escape: Enhanced intracellular delivery
• Stability: Improved nuclease resistance
• Manufacturing: Scalable synthetic production

Study Design

Phase 1/2a Adaptive Design

The trial employs a sophisticated adaptive design:

Dose-Escalation Phase

• Healthy Volunteer Cohort: Initial safety assessment
• Single Ascending Doses: Escalating doses to establish MTD
• Multiple Ascending Doses: Assessment of repeat dosing
• Early AD Cohort: Assessment in target population

Expansion Phase

• Efficacy Cohort: Patients with early AD
• Dose-Optimization: Refine dosing based on PK/PD
• Biomarker Assessment: Tau biomarkers as endpoints

Population

Healthy Volunteers

• Age 18-65 years
• Normal cognitive function
• No significant medical conditions
• Informed consent for participation

Early Alzheimer's Disease

• Diagnosis: NIA-AA criteria for MCI due to AD or mild AD dementia
• Age: Typical for early AD studies (55-85 years)
• Biomarker Confirmation: Evidence of tau pathology
• Stable Medications: No changes in AD medications for 4 weeks

Intervention

• Drug: ARO-MAPT-SC
• Route: Subcutaneous injection
• Schedule: Every 4 or 8 weeks
• Duration: Multiple doses over 12 months
• Control: Placebo (saline injection)

Key Eligibility Criteria

Inclusion

Exclusion

Primary Endpoints

Safety and Tolerability

• Treatment-Emergent Adverse Events (TEAEs)
• Serious Adverse Events (SAEs)
• Laboratory Abnormalities
• Vital Signs and ECG Changes

Pharmacokinetics (PK)

• Plasma Concentration: Drug levels over time
• Cerebrospinal Fluid (CSF): Drug penetration assessment
• Half-Life Determination: Dosing interval optimization

Pharmacodynamics (PD)

• MAPT mRNA Levels: Gene expression changes in CSF cells
• Tau Protein: Total tau and phosphorylated tau in CSF
• Biomarker Correlations: PK/PD relationship

Secondary Endpoints

• Cognitive Measures: Change in cognitive performance
• Brain Imaging: Tau PET changes
• Volumetric MRI: Brain atrophy rates
• Functional Outcomes: Activities of daily living

Scientific Rationale

Tau Hypothesis in Alzheimer's Disease

The tau protein hypothesis posits that accumulation of hyperphosphorylated tau protein into neurofibrillary tangles drives neuronal dysfunction and cell death in Alzheimer's disease[@bloom2022].

By reducing tau production at the genetic level, ARO-MAPT-SC aims to:

Therapeutic Window

The therapeutic rationale includes:

• Asymptomatic Period: Tau accumulation begins decades before symptoms
• Critical Threshold: Pathological accumulation exceeds clearance capacity
• Early Intervention: Reducing production before irreversible damage
• Disease Modification: Address root cause rather than symptoms

Rationale for Subcutaneous Administration

Subcutaneous delivery offers practical advantages:

• Patient Convenience: Office-based injection vs. intravenous
• Extended Exposure: Slower absorption, prolonged drug exposure
• Self-Administration: Potential for at-home dosing
• Dosing Flexibility: Multiple dose strengths available

Clinical Development Considerations

Biomarker Strategy

The trial incorporates comprehensive biomarker assessments:

CSF Biomarkers

• Total Tau: Marker of neuronal injury
• Phosphorylated Tau (p-tau181/217): Disease-specific tau pathology
• Neurofilament Light Chain (NfL): Neurodegeneration marker
• Beta-Amyloid: Concomitant AD pathology

Imaging Biomarkers

• Tau PET: Regional tau burden assessment
• Amyloid PET: Amyloid plaque quantification
• Volumetric MRI: Brain structure measurements
• FDG-PET: Metabolic activity assessment

Challenges in Tau-Targeting

Several challenges must be addressed:

Target Engagement

• Biomarker Validation: Confirm drug reaches target
• Dose Selection: Optimize based on CSF tau reduction
• PK/PD Modeling: Predict effective dosing

Clinical Endpoints

• Slow Disease Progression: Requires long trials
• Symptomatic Overlap: Difficult to isolate treatment effect
• Regulatory Acceptance: Biomarker endpoints as surrogates

Safety Considerations

• Off-Target Effects: Need selectivity for MAPT
• Long-Term Safety: Extended treatment implications
• Tau Reduction Safety: Confirm safety of reduced tau

Comparison with Other Tau-Targeting Approaches

Therapeutic Modalities

| Approach | Example | Mechanism | Stage | Administration |
|----------|---------|-----------|-------|----------------|
| ASO | ARO-MAPT-SC | MAPT mRNA knockdown | Phase 1/2a | Subcutaneous |
| ASO | BIIB080 (Biogen) | MAPT mRNA knockdown | Phase 2 | Intrathecal |
| Antibody | E2814 (Eisai) | Tau protein binding | Phase 2/3 | IV |
| Antibody | Gosuranemab (Roche) | Tau protein binding | Phase 2 | IV |
| Small Molecule | OGA Inhibitors | Tau O-GlcNAcylation | Phase 2 | Oral |

Unique Features of ARO-MAPT-SC

Regulatory Considerations

FDA Fast Track Designation

ARO-MAPT-SC has received fast track designation, which:

• Facilitates frequent communication with FDA
• Allows rolling review of data
• Provides guidance on accelerated approval pathways
• Recognizes unmet need in AD treatment

Biomarker-Driven Development

The development strategy incorporates:

• Surrogate Endpoints: CSF tau as predictive biomarker
• Accelerated Approval: Potential for earlier approval based on biomarkers
• Confirmatory Trials: Post-approval studies for clinical endpoints

Future Directions

Combination Therapy Potential

ARO-MAPT-SC may be combined with other approaches:

• Anti-Amyloid Therapies: Lecanemab, donanemab
• Anti-Neuroinflammation: Microglial modulators
• Symptomatic Treatments: AChEIs, NMDA antagonists

Disease Prevention

Beyond treatment, RNAi could enable prevention:

• Preclinical Intervention: Treatment before symptoms
• Genetic Risk Carriers: APOE4 homozygotes, PSEN1 carriers
• Primary Prevention: Population-based approaches

See Also

• [Arrowhead Pharmaceuticals](/companies/arrowhead-pharmaceuticals)
• [Tau Protein](/proteins/tau)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Anti-Tau Therapeutics](/therapeutics/anti-tau-therapeutics)
• [RNA Interference Therapeutics](/therapeutics/rna-interference-therapeutics)
• [Microtubule-Associated Protein Tau (MAPT) Gene](/genes/mapt)

External Links

• [Arrowhead Pharmaceuticals](https://www.arrowheadpharma.com)
• [ClinicalTrials.gov - NCT07221344](https://clinicaltrials.gov/study/NCT07221344)
• [PubMed - Tau in Alzheimer's](https://pubmed.ncbi.nlm.nih.gov/)

References